The global lancing device market is projected to reach $6.6 billion by 2033, driven by rising diabetes rates, technological advances in blood sampling, and increased demand for home-based health management, despite competition from continuous glucose monitoring systems.
Grand View Research says the global lancing device market was worth $3.5 billion in 2025 and is forecast to rise to $6.6 billion by 2033, reflecting an annual growth rate of 8.5% from 2026 to 2033. The report links that expansion to the growing number of people living with diabetes, wider use of self-monitoring blood glucose systems, and the shift towards home-based disease management. It also points to continued demand for convenient capillary blood sampling in both domestic and clinical settings.
The market remains anchored by single-use safety devices, which held the largest share in 2025, while home care was the biggest end-use segment and blood glucose monitoring the main application. Retail outlets remained the leading distribution route, helped by pharmacy and online access for patients who test regularly at home. Grand View Research also notes that adjustable-depth reusable devices are gaining traction because they allow more personalised use and can reduce ongoing costs for frequent testers.
Regional demand is still led by North America, which accounted for 42.5% of revenue in 2025, with the United States the largest national market. Asia Pacific is expected to grow fastest through 2033, supported by expanding healthcare access and a large diabetes burden. The International Diabetes Federation’s Diabetes Atlas 11th edition projects the number of adults living with diabetes worldwide will climb from 588.7 million in 2024 to 852.5 million by 2050, underscoring the scale of the long-term need for blood-sampling products. The same atlas says Africa, the Middle East and South-East Asia are set for especially sharp increases, which could widen demand for affordable monitoring tools.
At the same time, the category faces pressure from continuous glucose monitoring, which can reduce routine finger-stick testing for some patients. Grand View Research says that has not erased the need for lancing devices, but it has sharpened the focus on pain reduction, ergonomics and safety engineering. A separate Grand View Research outlook on the lancing devices segment within minimally invasive blood collection places the niche at $308.5 million in 2025, rising at a 7.4% CAGR to 2033, reinforcing the view that the category remains smaller but still steadily expanding within the broader diabetes-care market.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
